Guidelines for monitoring drug therapy in rheumatoid arthritis: American College of Rheumatology Ad Hoc Committee on Clinical Guidelines

Arthritis and Rheumatism

Volumn 39, Issue 5, 1996, Pages 723-731

  Simms, Robert W ^a,b   Kwoh, C Kent ^a,c   Anderson, Larry G ^a,d   Erlandson, Diane M ^a,e   Greene, Jerry M ^a,f   Kelleher, Mittie ^a,g   O'Dell, James R ^a,h   Partridge, Alison J ^a,i   Roberts, W Neal ^a,j   Robbins, Mark L ^a,k   Yood, Robert A ^a,l   Liang, Matthew H ^a,g  

^a Ad Hoc Comm on Clinical Guidelines ^*

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d Rheumatology Associates   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f VA BOSTON HEALTHCARE SYSTEM   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

ⁱ Robert B Brigham Multipurpose A   (United States)

^j VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k HARVARD PILGRIM HEALTH CARE   (United States)

^l Fallon Clinic   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; AURANOFIN; AUROTHIOGLUCOSE; AUROTHIOMALATE; AZATHIOPRINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GLUCOCORTICOID; GOLD DERIVATIVE; HYDROXYCHLOROQUINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; SALAZOSULFAPYRIDINE;

ARTICLE; BONE MARROW SUPPRESSION; DIGESTIVE SYSTEM ULCER; DRUG EFFECT; DRUG MONITORING; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INTRAMUSCULAR DRUG ADMINISTRATION; LUNG INFILTRATE; MYELOPROLIFERATIVE DISORDER; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEINURIA; RHEUMATOID ARTHRITIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG MONITORING; HUMANS; RHEUMATOLOGY;

EID: 0030000725     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.1780390503     Document Type: Article

References (68)

1. Liang MH, Fries JF: Containing costs in chronic disease monitoring strategies in the gold therapy of rheumatoid arthritis (editorial). J Rheumatol 5:241-244, 1978
2. Prashker MJ. Meenan RF: The total costs of drug therapy for rheumatoid arthritis: a model based on costs of drug, monitoring, and toxicity. Arthritis Rheum 38:318-325, 1995
3. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines: Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 39:713-722, 1996
4. Butt JH, Barthel JS, Moore RA: Clinical spectrum of the upper gastrointestinal effects of nonsteroidal anti-inflammatory drugs: natural history, symptomatology, and significance. Am J Med 84:5-14, 1988
5. Langman MJS: Ulcer complications and nonsteroidal antiinflammatory drugs. Am J Med 84:15-19, 1988
6. Corwin HL, Bonventre JV: Renal insufficiency associated with nonsteroidal anti-inflammatory agents. Am J Kidney Dis 4:147-152, 1984
7. Soll AH, Weinstein WM, Kurata J, McCarthy D: Non-steroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med 114:307-319, 1991
8. Furst DE: Are there differences among nonsteroidal antiinflammatory drugs? Comparing acetylated salicylates, nonacetylated salicylates, and nonacetylated nonsteroidal antiinflammatory drugs. Arthritis Rheum 37:1-9, 1994
9. Clive DM, Stoff JS: Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med 310:563-572, 1984
10. Blackshear JL, Napier JS, Davidman M, Stillman MT: Renal complications of nonsteroidal antiinflammatory drugs: identification and monitoring of those at risk. Semin Arthritis Rheum 14:163-175, 1985
11. Bender WL, Whelton A, Beschomer WE, Darwish MO, Hall-Craggs M, Solez K: Interstitial nephritis, proteinuria, and renal failure caused by nonsteroidal anti-inflammatory drugs. Am J Med 76:1006-1012, 1984
12. Murray MD, Brater DC: Adverse effects of nonsteroidal anti-inflammatory drugs on renal function. Ann Intern Med 112:559-560, 1990
13. Paulus HE: FDA Arthritis Advisory Committee Meeting: risks of agranulocytosis/aplastic anemia, flank pain, and adverse gastrointestinal effects with the use of nonsteroidal antiinflammatory drugs. Arthritis Rheum 30:593-595, 1987
14. Perneger TV, Whelton PK, Klag MJ: Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med 331:1675-1679, 1994
15. Ronco PM, Flahault A: Drug-induced end-stage renal disease (editorial). N Engl J Med 331:1711-1712, 1994
16. Sandier DP, Burr FR, Weinberg CR: Nonsteroidal antiinflammatory drugs and the risk for chronic renal disease. Ann Intern Med 115:165-172, 1991
17. Wagner EH: Nonsteroidal anti-inflammatory drugs and renal disease - still unsettled (editorial). Ann Intern Med 115:227-228, 1991
18. Benson GD: Hepatotoxicity following the therapeutic use of antipyretic analgesics. Am J Med 85:85-93, 1983
19. Fries JF: Assessing and understanding patient risk. Scand J Rheumatol 92:21-24, 1992
20. Silverstein FE, Graham DY, Serior JR, Davies HW, Struthers BJ, Bittman RM, Geis GS: Misoprostol reduces serious gastro-intestinal complications in patients with rheumatoid arthritis receiving non-steroidal anti-inflammatory drugs. Ann Intern Med 123:241-249, 1995
21. Levine JS: Misoprostol and non-steroidal anti-inflammatory drugs: a tale of effects, outcomes, and costs. Ann Intern Med 123:309-310, 1995
22. Roth SH: Efficacy of antacid therapy for NSAID-induced symptomatic gastropathy. Practical Gastroenterol 18:14-20, 1994
23. Agrawal NM, Roth S, Graham DY, White RH, Germain B, Brown JA: Misoprostol compared with sucralfate in the prevention of non-steroidal anti-inflammatory drug induced gastriculcer: a randomized, controlled trial. Ann Intern Med 115:195-200, 1991
24. Robinson MG, Griffin JW, Bowers J, Kogan FJ, Kogut DG, Lanza FL: Effect on ranitidine on gastro-duodenal mucosal damage induced by non-steroidal anti-inflammatory drugs. Dig Dis Sci 34:424-428, 1989
25. Walker AM, Bortnichak EA, Lanza L, Yood RA: The infrequency of liver function testing in patients using nonsteroidal antiinflammatory drugs. Arch Fam Med 4:24-29, 1995
26. Bernstein HN: Ocular safety of hydroxychloroquine sulfate (plaquenil). Ann Ophthalmol 23:292-296, 1991
27. Easterbrook M: Ocular effects and safety of antimalarial agents. Am J Med 85:23-29, 1988
28. Easterbrook M: The ocular safety of hydroxychloroquine. Semin Arthritis Rheum 23:62-67, 1993
29. Rynes RI: Ophthalmologic safety of long-term hydroxychloroquine sulfate treatment. Am J Med 84:35-39, 1983
30. Spalton DJ, Roe GMV, Hughes GRV: Hydroxychloroquine, dosage parameters and retinopathy. Lupus 2:355-358, 1993
31. Yancey C, White P: Guidelines for ophthalmologic examinations in children with juvenile rheumatoid arthritis. Pediatrics 92:295-296, 1993
32. Felson DT, Anderson JJ, Meenan RF: The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis: results of two metaanalyses. Arthritis Rheum 33:1449-1461, 1990
33. Mills PV, Beck M, Power BJ: Assessment of the retinal toxicity of hydroxychloroquine. Trans Opthalmol Soc UK 101:109-113, 1983
34. Mackenzie AH: Dose refinements in long term therapy of rheumatoid arthritis with antimalarials. Am J Med 75 (suppl 1A):40-45, 1983
35. Easterbrook M: The use of Amsler grids in early chloroquine retinopathy. Ophthalmology 91:1368-1372, 1984
36. Day RD: Sulfasalazine. In, Textbook of Rheumatology. Fourth edition. Edited by WN Kelley, ED Harris Jr, S Ruddy, CB Sledge. Philadelphia, WB Saunders, 1993
37. Amos RS, Pullar T, Bax DE, Situnayake D, Capell HA, McConkey B: Sulfasalazine for rheumatoid arthritis: toxicity for 774 patients monitored for 1 to 11 years. BMJ 293:420-423, 1986
38. Keisu M, Ekman E: Sulfasalazine associated agranulocytosis in Sweden 1972-1989. Eur J Clin Pharmacol 43:215-218, 1992
39. Toovey S, Hudson E, Hendry WF, Levi AJ: Sulfasalazine and male infertility: reversibility and possible mechanism. Gut 22: 445-451, 1981
40. Birnie GG, McLoed TI, Watkinson G: Incidence of sulfasalazine-induced male infertility. Gut 22:452-455, 1981
41. Walker AM, Funch D, Dreyer NA, Tolman KG, Kremer JM, Alarcón GS, Lee RG, Weinblatt ME: Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis Rheum 36:329-335, 1993
42. Weinblatt ME: Methotrexate. In, Textbook of Rheumatology. Fourth edition. Edited by WN Kelley, ED Harris Jr, S Ruddy, CB Sledge. Philadelphia, WB Saunders, 1993
43. Kremer JM, Alarcón GS, Lightfoot RW Jr, Willkens RF, Furst DE, Williams HJ, Dent PB, Weinblatt ME: Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. Arthritis Rheum 37:316-328, 1994
44. Bergquist SR, Felson DT, Prashker MJ, Freedberg KA: The cost-effectiveness of liver biopsy in rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 38:326-333, 1995
45. Weinblatt ME, Fraser P: Elevated mean corpuscular volume as a predictor of hematologic toxicity due to methotrexate therapy. Arthritis Rheum 32:1592-1596, 1989
46. Weinblatt ME: Toxicity of low dose methotrexate in rheumatoid arthritis. J Rheumatol 12 (suppl 12):35-39, 1985
47. Golden MR, Katz RS, Balk RA, Golden HE: The relationship of pre-existing lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis. J Rheumatol 22:1043-1047, 1995
48. Campbell PM, Wilske K, the Committee on Rheumatologic Care: Drug monitoring. In. Guidelines for Reviewers of Rheumatic Disease Care. Atlanta, American College of Rheumatology, 1989
49. Morgan SL, Baggott JE. Vaughn WH, Young PK, Austin JV, Krumdieck CL, Alarcón GS: The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 33:9-18, 1990
50. Morgan SL, Baggott JE, Vaughn WH, Austin JS, Veitch TA, Lee JY, Koopman WJ, Krumdieck CL, Alarcon GS: Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. Ann Intern Med 121:833-841, 1994
51. Roubenoff R, Hoyt J, Petri M, Hochberg MC, Hellman DB: Effects of antiinflammatory and immunosuppressive drugs on pregnancy and fertility. Semin Arthritis Rheum 18:88-110, 1988
52. Lederle Laboratories Division, American Cyanamid Company. Package insert for Rheumatrex, 1991
53. Ellman MH, Hurwitz H, Thomas C, Kozloff M: Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate. J Rheumatol 18:1741-1743, 1991
54. Kamel OW, van de Rijn M, Weiss LM, Del Zoppo GJ, Hench PK, Robbins BA, Montgomery PG, Warnke RA, Dorfman RF: Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 1317-1321, 1993
55. Kingsmore SF, Hall BD, Allen NB, Rice JR. Caldwell DS: Association of methotrexate, rheumatoid arthritis and lymphoma: report of 2 cases and literature review. J Rheumatol 19:1462-1465, 1992
56. Moder KG, Tefferi A, Cohen MD, Menke DM, Luthra HS: Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: a retrospective study. Am J Med 99:276-281, 1995
57. Lockie LM, Smith DM: Forty-seven years experience with gold therapy in 1019 rheumatoid arthritis patients. Semin Arthritis Rheum 14:238-246, 1985
58. Davis P. Hughes GRV: Significance of eosinophilia during gold therapy. Arthritis Rheum 17:964-968, 1974
59. Gerber RC, Paulus HE: Gold therapy. Rheum Dis Clin North Am 1:307-318, 1975
60. Gordon DA: Gold compounds in the rheumatic diseases. In, Textbook of Rheumatology. Fourth edition. Edited by WN Kelley, ED Harris Jr. S Ruddy, CB Sledge. Philadelphia, WB Saunders, 1993
61. Jaffe IA: Penicillamine. In, Textbook of Rheumatology. Fourth edition. Edited by WN Kelley, ED Harris Jr, S Ruddy, CB Sledge. Philadelphia, WB Saunders, 1993
62. Singh G, Fries JF, Spitz P, Williams CA: Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective. Arthritis Rheum 32:837-843, 1989
63. US Preventive Services Task Force: Guide to Clinical Preventive Services: Assessment of the Effectiveness of 169 Interventions. Edited by M Fisher. Baltimore, Williams and Wilkins, 1989
64. Fauci CS, Young KR: Immunoregulatory agents. In, Textbook of Rheumatology. Fourth edition. Edited by WN Kelley, ED Harris Jr, S Ruddy, CB Sledge. Philadelphia, WB Saunders, 1993
65. Briggs GG, Freeman RK, Yaffe SJ: Drugs in pregnancy and lactation. Fourth edition. Baltimore, Williams and Wilkins, 1994
66. Needs CJ, Brooks PM: Antirheumatic medication during lactation. Br J Rheumatol 24:291-297, 1985
67. Anderson PO: Drugs and breast feeding. In, Handbook of Clinical Drug Data. Seventh edition. Edited by JE Kroben, PO Anderson. WG Troutman, LJ David, Hamilton, IL, Drug Intelligence Publications, 1993
68. Anderson AJ: Drugs in pregnancy. In, Handbook of Clinical Drug Data. Seventh edition. Edited by JE Kroben, PO Anderson, WG Troutman, LJ David. Hamilton, IL, Drug Intelligence Publications, 1993